EP 2007423 A2 20081231 - CTLA4 ANTIBODY COMBINATION THERAPY
Title (en)
CTLA4 ANTIBODY COMBINATION THERAPY
Title (de)
CTLA4-ANTIKÖRPER-KOMBINATIONSTHERAPIE
Title (fr)
POLYTHÉRAPIE À BASE D'UN ANTICORPS ANTI-CTLA4
Publication
Application
Priority
- IB 2007000860 W 20070326
- US 78966206 P 20060405
Abstract (en)
[origin: WO2007113648A2] The invention relates to administration of an anti-CTLA4 antibody, particularly human antibodies to human CTLA4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, CP-675,206 (11.2.1), and ipilimumab, in combination with a therapeutic agent for treatment of cancer. An exemplary method of the invention comprises administering an anti-CTLA4 antibody, preferably, CP-675,206, and a chemotherapeutic agent, preferably, gemcitabine, for treatment of pancreatic cancer, among other treatment modalities.
IPC 8 full level
A61K 39/395 (2006.01); A61P 31/18 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC (source: EP)
A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61P 31/18 (2017.12); A61P 35/00 (2017.12); A61P 35/02 (2017.12); A61P 43/00 (2017.12); C07K 16/2818 (2013.01); C07K 16/2887 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01)
Citation (search report)
See references of WO 2007113648A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK RS
DOCDB simple family (publication)
WO 2007113648 A2 20071011; WO 2007113648 A3 20080320; AR 060306 A1 20080604; CA 2647282 A1 20071011; EP 2007423 A2 20081231; JP 2007277242 A 20071025; TW 200808348 A 20080216
DOCDB simple family (application)
IB 2007000860 W 20070326; AR P070101443 A 20070404; CA 2647282 A 20070326; EP 07734181 A 20070326; JP 2007098711 A 20070404; TW 96112050 A 20070404